MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00262-024-03796-1

Медицинская библиотека · Cancer immunology, immunotherapy : CII · 2024

Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration.

Lu Yunxin, Jin Yin, Liu Furong, Wang Zixian, Zhou Wen, Zhang Yang, Bai Bing, Wang Yun, Wang Zhiqiang, Nie Man, Luo Huiyan, Wei Xiaoli, Liang Chuqiao, Guo Guifang, Qiu Miaozhen, Chen Jianwen, Liu Yu, Li Shengping, Li Yuhong, Wang Fenghua, Wang Feng, Chi Peidong, Zhang Dongsheng

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

The anti-PD-L1 antibody durvalumab has been approved for use in first-line advanced biliary duct cancer (ABC). So far, predictive biomarkers of efficacy are lacking.

METHODS

ABC patients who underwent gemcitabine-based chemotherapy with or without durvalumab were retrospectively enrolled, and their baseline clinical pathological indices were retrieved from medical records. Overall (OS) and progression free survival (PFS) were calculated and analyzed. The levels of peripheral biomarkers from 48 patients were detected with assay kits including enzyme-linked immunosorbent assay. Genomic alterations in 27 patients whose tumor tissues were available were depicted via targeted next-generation sequencing.

RESULTS

A total of 186 ABC patients met the inclusion criteria between January 2020 and December 2022 were finally enrolled in this study. Of these, 93 patients received chemotherapy with durvalumab and the rest received chemotherapy alone. Durvalumab plus chemotherapy demonstrated significant improvements in PFS (6.77 vs. 4.99 months; hazard ratio 0.65 [95% CI 0.48-0.88]; P = 0.005), but not OS (14.29 vs. 13.24 months; hazard ratio 0.91 [95% CI 0.62-1.32]; P = 0.608) vs. chemotherapy alone in previously untreated ABC patients. The objective response rate (ORR) in patients receiving chemotherapy with and without durvalumab was 19.1% and 7.8%, respectively. Pretreatment sPD-L1, CSF1R and OPG were identified as significant prognosis predictors in patients receiving durvalumab. ADGRB3 and RNF43 mutations were enriched in patients who responded to chemotherapy plus durvalumab and correlated with superior survival.

CONCLUSION

This retrospective real-world study confirmed the clinical benefit of durvalumab plus chemotherapy in treatment-naïve ABC patients. Peripheral sPD-L1 and CSF1R are promising prognostic biomarkers for this therapeutic strategy. Presence of ADGRB3 or RNF43 mutations could improve the stratification of immunotherapy outcomes, but further studies are warranted to explore the underlying mechanisms.

Для цитирования: Lu Yunxin, Jin Yin, Liu Furong, Wang Zixian, Zhou Wen, Zhang Yang, Bai Bing, Wang Yun, Wang Zhiqiang, Nie Man, Luo Huiyan, Wei Xiaoli, Liang Chuqiao, Guo Guifang, Qiu Miaozhen, Chen Jianwen, Liu Yu, Li Shengping, Li Yuhong, Wang Fenghua, Wang Feng, Chi Peidong, Zhang Dongsheng. Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration.. Cancer immunology, immunotherapy : CII. 2024. DOI: 10.1007/s00262-024-03796-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.